Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee

• Status: Terminated
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of MEDI-578, a monoclonal antibody, in patients with osteoarthritis of the knee. It will also be evaluated how MEDI-578 is absorbed and distributed through the body.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: MedImmune LLC

Criteria

Inclusion Criteria:

• Patients with painful osteoarthritis of the knee.

• The pain from the knee must exceed pain experienced from any other condition.

• Patients must be willing and able to discontinue all current analgesic treatment.

Exclusion Criteria:

• Any other form of arthritis than osteoarthritis.

• Presence of neuropathic pain, or fibromyalgia, or wide spread chronic pain not related to osteoarthritis.

• Significant abnormalities on the clinical examination that may interfere with the study or present a safety risk to the patient, as judged by the investigator.